<DOC>
	<DOCNO>NCT01655693</DOCNO>
	<brief_summary>The purpose phase III study determine whether Doxorubicin Transdrug ( DT ) effective treatment patient suffer advanced Hepatocellular Carcinoma ( HCC ) failure intolerance Sorafenib . Patients HCC without cirrhosis good liver function eligible . Only benefit treatment efficacy demonstrate eligible . These patient usually propose either best standard care ( BSC ) participation clinical trial . Patients eligible RELIVE study receive either DT 20 mg/m2 DT 30 mg/m2 BSC .</brief_summary>
	<brief_title>Efficacy Safety Doxorubicin Transdrug Study Patients Suffering From Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description>Doxorubicin-Transdrug™ ( DT ) nanoparticle formulation doxorubicin.In vitro vivo model , DT show overcome multidrug resistance ( MDR ) effective doxorubicin sensitive resistant tumour model particular X/myc bi-transgenic MDR murine model HCC .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Male nonpregnant , nonbreast feed female ; Aged ≥ 18 year ; Patient : advanced HCC ( BCLCC accord BCLC stag classification ) progress Sorafenib therapy intolerant Sorafenib , ; intermediate HCC ( BCLCB ) non eligible non responder transarterial chemoembolization ( TACE ) , progress intolerant Sorafenib therapy Patients porta hepatis lymph node , extrahepatic metastasis , portal/suprahepatic vein thrombosis without extension inferior/superior vena cava , eligible ; HCC diagnose accord AASLD and/or EASL criterion : Radiological Criteria applicable cirrhotic liver : Nodule ≥ 10 mm : one imaging technique among MRI CTscan show typical appearance HCC define arterial enhancement rapid washout portal venous delay phase ; If appearance typical HCC initial imaging : second contrast enhance study ( CT MRI ) show typical appearance HCC define arterial enhancement rapid washout portal venous delay phase ; And/Or cytohistology criterion ( e.g . case atypical lesion HCC imaging , absence cirrhosis ) ; Without cirrhosis non decompensated cirrhosis ( ChildPugh score A5 B7 include ) ; ECOG Performance Status 0 1 ; Laboratory test follow : Platelets ≥ 50,000 /mm3 Neutrophil count ≥ 1000/mm3 Hemoglobin ≥ 10g/dL Serum transaminase &lt; 5 ULN ( NCI/CTC grade 0 , 1 , 2 ) Alkaline phosphatases &lt; 5 ULN ( NCI/CTC grade 0 , 1 , 2 ) Serum bilirubin &lt; 35 µM/L ( 2.0 mg/dL ) ; Signed date write informed consent form . Cirrhosis ChildPugh score B8C15 ; Untreated chronic hepatitis B ; Patients eligible curative treatment ( transplantation , surgical resection , percutaneous treatment ) ; Patients eligible palliative treatment demonstrate efficacy : TACE , Sorafenib ; Patients fail Sorafenib treatment intolerant sorafenib eligible include Sorafenib stop least 2 week randomization ; Prior history malignancy exception adequately treat basal cell carcinoma situ cervical cancer complete remission since five year least ; HCC develop transplant liver ; HIV infection ; Risk variceal bleed ; SaO2 &lt; 95 % ; Presence significant acute chronic respiratory disease define NCI/CTCAE &gt; grade 2 ; Presence recent ( &lt; 6 month ) current cardiac failure ( class III IV NYHA classification ) , recent ( &lt; 6 month ) acute coronary syndrome , clinically significant ECG abnormality recent ( less 6 month ) acute vascular disease ( stroke , MI… ) ; Prior cumulative dose 300 mg/m² doxorubicin equivalent ; Patients currently treat immunosuppressive agent stop ; Patients whose medical surgical condition unstable may allow study completion compliance , specially patient uncontrolled diabetes ; Uncontrolled systemic infection ; Patients life expectancy le 2 month ; Patients receive experimental drug another clinical trial last 30 day prior randomization present clinical trial ; Women childbearing age unwilling unable use effective contraception method study treatment period 6 month last administration study drug , male partner ( ) refuse use condom ( applicable ) ; Men unwilling unable use condom study treatment period 6 month last administration study drug , female partner ( ) refuse use one appropriate effective contraception method ( applicable ) ; Patients unwilling unable comply protocol requirement schedule visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Intermediate/advanced hepatocellular carcinoma</keyword>
	<keyword>After failure intolerance Sorafenib .</keyword>
</DOC>